CA Stock MarketDetailed Quotes

AGN Algernon Pharmaceuticals Inc

Watchlist

0.085
0.0000.00%

15min DelayMarket Closed Nov 1 13:41 ET

2.32MMarket Cap-2500P/E (TTM)

Algernon Pharmaceuticals Inc Key Stats

Cash Flow

Quarterly+Annual

YOY

Hide blank lines

(Q3)May 31, 2024

(Q2)Feb 29, 2024

(Q1)Nov 30, 2023

(FY)Aug 31, 2023

(Q4)Aug 31, 2023

(Q3)May 31, 2023

(Q2)Feb 28, 2023

(Q1)Nov 30, 2022

(FY)Aug 31, 2022

(Q4)Aug 31, 2022

Operating Cash Flow (Indirect Method)

Cash flow from continuing operating activities

-143.65%-1.79M

45.70%-239.05K

93.53%-52.24K

12.35%-2.55M

61.08%-572.71K

21.18%-732.94K

48.22%-440.22K

-338.14%-807.14K

62.77%-2.91M

-80.72%-1.47M

Net income from continuing operations

228.09%1.44M

19.53%-1M

72.26%-521.55K

-12.01%-6.78M

-13.95%-2.53M

-40.80%-1.13M

32.05%-1.25M

-56.60%-1.88M

21.72%-6.05M

-822.80%-2.22M

Operating gains losses

-14,511.01%-1.91M

-129.18%-6.41K

-56.82%10.82K

263.89%73.95K

162.81%13.65K

35,770.27%13.27K

255.08%21.97K

370.68%25.05K

-248.48%-45.12K

77.21%-21.73K

Depreciation and amortization

-52.58%6.09K

-39.04%7.64K

-36.46%7.43K

44.26%50.4K

-53.00%13.34K

552.70%12.83K

173.23%12.54K

--11.69K

--34.94K

--28.38K

Asset impairment expenditure

----

4,125.19%1.54M

----

--36.48K

----

Remuneration paid in stock

-68.57%61.01K

-60.46%156.61K

-88.43%69.04K

136.76%1.26M

-69.50%69.8K

1,256.22%194.1K

37.70%396.12K

--596.8K

-35.84%530.84K

298.69%228.86K

Other non cashItems

----

--40K

----

Change In working capital

-894.81%-1.38M

61.17%607.01K

-13.05%382.03K

-51.03%1.27M

-41.81%275.59K

219.59%174.15K

-46.79%376.64K

-71.63%439.34K

532.28%2.58M

305.05%473.58K

-Change in receivables

17.94%21.92K

-113.79%-16.69K

-81.98%81.72K

-64.83%567.8K

84.60%-25.22K

151.42%18.58K

178.94%121.01K

-76.96%453.43K

240.31%1.61M

-139.81%-163.71K

-Change in prepaid assets

-163.42%-52.34K

-93.21%17.31K

-74.43%85.45K

215.37%634.37K

93.55%-37.24K

1,582.20%82.53K

377.09%254.93K

1,737.27%334.15K

-398.61%-549.84K

-358.31%-577.3K

-Change in payables and accrued expense

-1,953.40%-1.35M

86,280.48%606.39K

153.44%186.11K

-95.82%63.54K

-72.17%338.05K

170.28%73.04K

-99.91%702

12.60%-348.25K

312.28%1.52M

240.30%1.21M

-Change in other working capital

--0

--28.75K

----

Cash from discontinued investing activities

Operating cash flow

-143.65%-1.79M

45.70%-239.05K

93.53%-52.24K

12.35%-2.55M

61.08%-572.71K

21.18%-732.94K

48.22%-440.22K

-338.14%-807.14K

62.77%-2.91M

-80.72%-1.47M

Investing cash flow

Cash flow from continuing investing activities

8,640.70%2.31M

-152.13%-23.12K

58.85%-59.5K

88.63%-5.58K

-151.17%-27.01K

79.50%-9.17K

55.71%-17.74K

-16.20%-144.61K

-372.51%-49.07K

Net intangibles purchas and sale

10,038.86%2.68M

-152.13%-23.12K

--0

58.85%-59.5K

88.63%-5.58K

-151.17%-27.01K

79.50%-9.17K

55.71%-17.74K

-16.20%-144.61K

-372.51%-49.07K

Cash from discontinued investing activities

Investing cash flow

8,640.70%2.31M

-152.13%-23.12K

--0

58.85%-59.5K

88.63%-5.58K

-151.17%-27.01K

79.50%-9.17K

55.71%-17.74K

-16.20%-144.61K

-372.51%-49.07K

Financing cash flow

Cash flow from continuing financing activities

-99.23%7.5K

1,645.46%265.57K

-35.34%1.33M

-86.90%269.17K

974K

-17.18K

102.93K

-51.59%2.06M

3,725.00%2.06M

Net common stock issuance

--0

----

-40.35%1.23M

-91.86%167.25K

--1.05M

----

-23.70%2.06M

5,037.81%2.06M

Proceeds from stock option exercised by employees

--7.5K

--0

--102.93K

--0

--102.93K

--0

Net other financing activities

----

---80.2K

----

Cash from discontinued financing activities

Financing cash flow

-99.23%7.5K

1,645.46%265.57K

--0

-35.34%1.33M

-86.90%269.17K

--974K

---17.18K

--102.93K

-51.59%2.06M

3,725.00%2.06M

Net cash flow

Beginning cash position

-65.42%76.28K

-89.25%74.17K

-91.12%125.09K

-41.58%1.41M

-50.25%434.23K

-87.84%220.59K

-74.43%689.7K

-41.58%1.41M

-60.61%2.41M

-73.45%872.84K

Current changes in cash

147.05%528.8K

100.73%3.41K

92.76%-52.24K

-28.07%-1.28M

-157.84%-309.12K

122.75%214.05K

47.86%-466.58K

-341.55%-721.95K

72.93%-1M

160.64%534.44K

Effect of exchange rate changes

1,218.09%4.45K

48.88%-1.3K

-57.75%1.33K

140.89%175

-102.12%-26

-278.48%-398

-122.83%-2.54K

124.14%3.14K

94.91%-428

-73.04%1.23K

End cash Position

40.37%609.52K

-65.42%76.28K

-89.25%74.17K

-91.12%125.09K

-50.25%434.23K

-87.84%220.59K

-74.43%689.7K

-41.58%1.41M

Free cash from

-138.89%-1.82M

41.66%-262.17K

93.67%-52.24K

14.55%-2.61M

61.97%-578.29K

19.21%-759.95K

49.78%-449.39K

-375.99%-824.88K

61.53%-3.06M

-84.39%-1.52M

Accounting Standards

US-GAAP

Audit Opinions

Unqualified Opinion with Explanatory Notes

	(Q3)May 31, 2024	(Q2)Feb 29, 2024	(Q1)Nov 30, 2023	(FY)Aug 31, 2023	(Q4)Aug 31, 2023	(Q3)May 31, 2023	(Q2)Feb 28, 2023	(Q1)Nov 30, 2022	(FY)Aug 31, 2022	(Q4)Aug 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities	-143.65%-1.79M	45.70%-239.05K	93.53%-52.24K	12.35%-2.55M	61.08%-572.71K	21.18%-732.94K	48.22%-440.22K	-338.14%-807.14K	62.77%-2.91M	-80.72%-1.47M
Net income from continuing operations	228.09%1.44M	19.53%-1M	72.26%-521.55K	-12.01%-6.78M	-13.95%-2.53M	-40.80%-1.13M	32.05%-1.25M	-56.60%-1.88M	21.72%-6.05M	-822.80%-2.22M
Operating gains losses	-14,511.01%-1.91M	-129.18%-6.41K	-56.82%10.82K	263.89%73.95K	162.81%13.65K	35,770.27%13.27K	255.08%21.97K	370.68%25.05K	-248.48%-45.12K	77.21%-21.73K
Depreciation and amortization	-52.58%6.09K	-39.04%7.64K	-36.46%7.43K	44.26%50.4K	-53.00%13.34K	552.70%12.83K	173.23%12.54K	--11.69K	--34.94K	--28.38K
Asset impairment expenditure	----	----	----	4,125.19%1.54M	----	----	----	----	--36.48K	----
Remuneration paid in stock	-68.57%61.01K	-60.46%156.61K	-88.43%69.04K	136.76%1.26M	-69.50%69.8K	1,256.22%194.1K	37.70%396.12K	--596.8K	-35.84%530.84K	298.69%228.86K
Other non cashItems	----	----	----	--40K	----	----	----	----	----	----
Change In working capital	-894.81%-1.38M	61.17%607.01K	-13.05%382.03K	-51.03%1.27M	-41.81%275.59K	219.59%174.15K	-46.79%376.64K	-71.63%439.34K	532.28%2.58M	305.05%473.58K
-Change in receivables	17.94%21.92K	-113.79%-16.69K	-81.98%81.72K	-64.83%567.8K	84.60%-25.22K	151.42%18.58K	178.94%121.01K	-76.96%453.43K	240.31%1.61M	-139.81%-163.71K
-Change in prepaid assets	-163.42%-52.34K	-93.21%17.31K	-74.43%85.45K	215.37%634.37K	93.55%-37.24K	1,582.20%82.53K	377.09%254.93K	1,737.27%334.15K	-398.61%-549.84K	-358.31%-577.3K
-Change in payables and accrued expense	-1,953.40%-1.35M	86,280.48%606.39K	153.44%186.11K	-95.82%63.54K	-72.17%338.05K	170.28%73.04K	-99.91%702	12.60%-348.25K	312.28%1.52M	240.30%1.21M
-Change in other working capital	--0	--0	--28.75K	----	----	----	----	----	----	----
Cash from discontinued investing activities
Operating cash flow	-143.65%-1.79M	45.70%-239.05K	93.53%-52.24K	12.35%-2.55M	61.08%-572.71K	21.18%-732.94K	48.22%-440.22K	-338.14%-807.14K	62.77%-2.91M	-80.72%-1.47M
Investing cash flow
Cash flow from continuing investing activities	8,640.70%2.31M	-152.13%-23.12K	0	58.85%-59.5K	88.63%-5.58K	-151.17%-27.01K	79.50%-9.17K	55.71%-17.74K	-16.20%-144.61K	-372.51%-49.07K
Net intangibles purchas and sale	10,038.86%2.68M	-152.13%-23.12K	--0	58.85%-59.5K	88.63%-5.58K	-151.17%-27.01K	79.50%-9.17K	55.71%-17.74K	-16.20%-144.61K	-372.51%-49.07K
Cash from discontinued investing activities
Investing cash flow	8,640.70%2.31M	-152.13%-23.12K	--0	58.85%-59.5K	88.63%-5.58K	-151.17%-27.01K	79.50%-9.17K	55.71%-17.74K	-16.20%-144.61K	-372.51%-49.07K
Financing cash flow
Cash flow from continuing financing activities	-99.23%7.5K	1,645.46%265.57K	0	-35.34%1.33M	-86.90%269.17K	974K	-17.18K	102.93K	-51.59%2.06M	3,725.00%2.06M
Net common stock issuance	--0	----	----	-40.35%1.23M	-91.86%167.25K	--1.05M	----	----	-23.70%2.06M	5,037.81%2.06M
Proceeds from stock option exercised by employees	--7.5K	--0	--0	--102.93K	--0	--0	--0	--102.93K	--0	--0
Net other financing activities	----	----	----	----	----	---80.2K	----	----	----	----
Cash from discontinued financing activities
Financing cash flow	-99.23%7.5K	1,645.46%265.57K	--0	-35.34%1.33M	-86.90%269.17K	--974K	---17.18K	--102.93K	-51.59%2.06M	3,725.00%2.06M
Net cash flow
Beginning cash position	-65.42%76.28K	-89.25%74.17K	-91.12%125.09K	-41.58%1.41M	-50.25%434.23K	-87.84%220.59K	-74.43%689.7K	-41.58%1.41M	-60.61%2.41M	-73.45%872.84K
Current changes in cash	147.05%528.8K	100.73%3.41K	92.76%-52.24K	-28.07%-1.28M	-157.84%-309.12K	122.75%214.05K	47.86%-466.58K	-341.55%-721.95K	72.93%-1M	160.64%534.44K
Effect of exchange rate changes	1,218.09%4.45K	48.88%-1.3K	-57.75%1.33K	140.89%175	-102.12%-26	-278.48%-398	-122.83%-2.54K	124.14%3.14K	94.91%-428	-73.04%1.23K
End cash Position	40.37%609.52K	-65.42%76.28K	-89.25%74.17K	-91.12%125.09K	-91.12%125.09K	-50.25%434.23K	-87.84%220.59K	-74.43%689.7K	-41.58%1.41M	-41.58%1.41M
Free cash from	-138.89%-1.82M	41.66%-262.17K	93.67%-52.24K	14.55%-2.61M	61.97%-578.29K	19.21%-759.95K	49.78%-449.39K	-375.99%-824.88K	61.53%-3.06M	-84.39%-1.52M
Accounting Standards	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP
Audit Opinions	--	--	--	Unqualified Opinion with Explanatory Notes	--	--	--	--	Unqualified Opinion with Explanatory Notes	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

AGN Algernon Pharmaceuticals Inc

Algernon Pharmaceuticals Inc Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow